Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
复制标题
DOI：
10.3390/antibiotics10111294
复制
发表时间：
2021-10-23
期刊：
影响因子：
--
通讯作者：
Ko WC
中科院分区：
文献类型：
--
作者：
Lee CC;Hsieh CC;Ko WC
自2019年12月以来，严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）迅速导致全球大流行，造成约400万人死亡。目前迫切需要有效的口服抗病毒药物来治疗冠状病毒病-2019 (COVID-19)，阻断SARS-CoV-2的传播，并防止病情发展为严重疾病。Molnupiravir（原EIDD-2801）是β -d- n4 -羟基胞苷（EIDD-1931）的前药和RNA依赖性RNA聚合酶抑制剂，具有显著的抗SARS-CoV-2活性。其预防作用已在雪貂模型中得到证实。两项i期试验（NCT04392219和NCT04746183）已经证明口服molnupiravir在治疗剂量下是安全且耐受性良好的。两项ii期临床试验（NCT04405739和nct04405570）显示，口服莫努匹拉韦治疗5天后，通过消除早期和轻度COVID-19患者的鼻咽病毒来评估其令人满意的疗效。两项ii /III期试验NCT04575597和NCT04575584正在进行中，估计分别有1850例和304例入组。NCT04575597最近发布，molnupiravir显着降低了患有轻度或中度COVID-19的成人住院或死亡的风险。为了造福个人和公众健康，可以期待molnupiravir的临床应用，以及时治疗COVID-19患者并预防SARS-CoV-2的传播。
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-d-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral molnupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT 04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respectively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.
登录
查看更多内容
影响因子：
3.7
作者：
Kandeel M;Yamamoto M;Tani H;Kobayashi A;Gohda J;Kawaguchi Y;Park BK;Kwon HJ;Inoue JI;Alkattan A
通讯作者：
Alkattan A
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
DOI：
10.1016/j.trsl.2019.12.002
发表时间：
2020-04
期刊：
Translational research : the journal of laboratory and clinical medicine
影响因子：
--
作者：
Toots M;Yoon JJ;Hart M;Natchus MG;Painter GR;Plemper RK
通讯作者：
Plemper RK
影响因子：
7.6
作者：
Painter, George R.;Bowen, Richard A.;Kolykhalov, Alexander A.
通讯作者：
Kolykhalov, Alexander A.
影响因子：
12.7
作者：
Caruso A;Caccuri F;Bugatti A;Zani A;Vanoni M;Bonfanti P;Cazzaniga ME;Perno CF;Messa C;Alberghina L
通讯作者：
Alberghina L